Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD)

By In The News
March 6, 2019 in The Headlines

Recommended Posts

In The News

Posted March 6, 2019

- Share

Posted March 6, 2019

DUBLIN, March 6, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced topline results from three pivotal studies of rapastinel as an adjunctive treatment of Major Depressive Disorder (MDD). In three acute studies (RAP-MD-01,-02,-03), the rapastinel treatment arms did not...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  220066
2. Jaydee
  16871
3. Kip Powick
  12237
4. deicer
  12233
5. dagger
  9596
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  270.4k
- Total Posts
  
  559.2k

Sign In

Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD)

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support